Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
复制标题
DOI：
10.1016/j.bbmt.2010.02.015
复制
发表时间：
2010-08
影响因子：
4.3
通讯作者：
Qazilbash, Muzaffar H.
中科院分区：
文献类型：
--
作者：
Efebera, Yvonne A.;Qureshi, Sofia R.;Cole, Suzanne M.;Saliba, Rima;Pelosini, Matteo;Patel, Ronak M.;Koca, Ebru;Mendoza, Floralyn L.;Wang, Michael;Shah, Jatin;Alousi, Amin;Hosing, Chitra;Popat, Uday;Kebriaei, Partow;Anderlini, Paolo;Khouri, Issa F.;Champlin, Richard;Giralt, Sergio;Qazilbash, Muzaffar H.
尽管最近取得了进展，但多发性骨髓瘤仍然无法治愈，大多数患者最终会发展为进行性疾病。同种异体造血干细胞移植（allo HCT）为10-20%的复发或难治性疾病患者提供了潜在的治疗选择。我们评估了在我院接受低强度调节（RIC）治疗复发和/或难治性骨髓瘤的患者的预后。在1996年至2006年间接受RIC同种异体HCT治疗的51例重度预处理的复发骨髓瘤患者纳入了本分析。从诊断到HCT的中位时间为34个月。存活患者中位随访时间为27个月（3-98）。1年累计移植相关死亡率（TRM）为25%。2年无进展生存期（PFS）和总生存期（OS）分别为19%和32%。II-IV级急性或慢性移植物抗宿主病（GVHD）的发生率分别为27%和47%。在本分析时，12例患者（24%）存活，其中7例（14%）在接受移植后缓解期长达6年。较低的β2微球蛋白（<3.3）和先前的自体移植预示着较低的NRM，较长的PFS和OS。在复发或难治性骨髓瘤中，采用RIC方案的同种异体HCT具有可接受的毒性和持久的缓解和生存。在病程早期使用RIC允许的HCT可能会提供更大的益处。
Despite recent advances, multiple myeloma remains incurable and most patients eventually develop progressive disease. Allogeneic hematopoietic stem cell transplantation (allo HCT) offers a potentially curative option in 10–20% of patients with relapsed or refractory disease. We evaluated the outcome of patients undergoing allo HCT with reduced-intensity conditioning (RIC) for relapsed and/or refractory myeloma at our institution. Fifty-one patients with heavily pretreated, relapsed myeloma, who received RIC allo HCT between 1996 and 2006, were included in this analysis. Median time from diagnosis to allo HCT was 34 months. Median follow-up in surviving patients was 27 months (3–98). Cumulative transplant-related mortality (TRM) at 1 year was 25%. Progression-free survival (PFS) and overall survival (OS) at 2 years were 19% and 32%, respectively. The incidence of grade II-IV acute or chronic graft-vs-host disease (GVHD) was 27% and 47%, respectively. At the time of this analysis, 12 patients (24%) were alive 7 of whom (14%) were in remission for up to 6 years after allo SCT. A lower β2 microglobulin (<3.3) and a prior autotransplant predicted a lower NRM, longer PFS and OS. Allo HCT with RIC regimens is associated with acceptable toxicity and durable remission and survival in relapsed or refractory myeloma. Use of RIC allo HCT earlier in the course of the disease may offer greater benefit.
登录
查看更多内容
影响因子：
20.3
作者：
Kröger, N;Sayer, HG;Zander, AR
通讯作者：
Zander, AR
影响因子：
10.3
作者：
Kumar, Ambuj;Kharfan-Dabaja, Mohamed A.;Djulbegovic, Benjamin
通讯作者：
Djulbegovic, Benjamin
影响因子：
45.3
作者：
Barlogie, B;Kyle, RA;Crowley, JC
通讯作者：
Crowley, JC
影响因子：
158.5
作者：
Bruno, Benedetto;Rotta, Marcello;Boccadoro, Mario
通讯作者：
Boccadoro, Mario
影响因子：
4.8
作者：
de Lavallade, H.;El-Cheikh, J.;Mohty, M.
通讯作者：
Mohty, M.